Lyra Therapeutics raises $30m for chronic rhinosinusitis drug candidates
Lyra Therapeutics has raised $30 million in a Series C financing round to advance its lead product candidates for the treatment of chronic rhinosinusitis (CRS). Known as an inflammatory disease of the paranasal sinuses, chronic rhinosinusitis is said to affect around 14 million people in the US. The lead product candidates of the US-based clinical-stage […]